How were Correvio Pharma's earnings last quarter?

Correvio Pharma Corp (NASDAQ:CORV) released its earnings results on Monday, March, 30th. The company reported ($0.07) earnings per share for the quarter, beating analysts' consensus estimates of ($0.13) by $0.06. The company had revenue of $11.33 million for the quarter, compared to analysts' expectations of $11.52 million. Correvio Pharma had a negative net margin of 107.81% and a negative trailing twelve-month return on equity of 2,128.82%.

What other stocks do shareholders of Correvio Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Correvio Pharma investors own include Inovio Pharmaceuticals (INO) , Outlook Therapeutics (OTLK) , SCYNEXIS (SCYX) , Heat Biologics (HTBX) , Actinium Pharmaceuticals (ATNM) , Acasti Pharma (ACST) , Biocept (BIOC) , Vaxart (VXRT) , Co-Diagnostics (CODX) .

NASDAQ:CORV

Correvio Pharma (CORV) Stock Price, News & Analysis

→ A.I. “Perfect Storm” Could Send THESE Stocks Sky High (From InvestorPlace) (Ad)

Free CORV Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $0.42
▼
$0.42
50-Day Range: $0.39
▼
$0.42
52-Week Range: $0.21
▼
$2.79

Volume: N/A
Average Volume: 5.35 million shs
Market Capitalization: $27.80 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Correvio Pharma alerts:

Ad InvestorPlace

“Forget Tesla, this is Elon’s Next Big Thing”

According to Forbes, this breakthrough could define the future of AI. Most people don’t know about it… Because it was found 750 miles away from Silicon Valley.

Click here to see the details.

About Correvio Pharma

Correvio Pharma Corp., a specialty pharmaceutical company, engages in developing therapeutics worldwide. Its portfolio of marketed brands comprise Aggrastat (tirofiban hydrochloride) for patients with acute coronary syndrome; and Brinavess (vernakalant IV) for the rapid conversion of recent onset atrial fibrillation to sinus rhythm. The company also offers ESMOCARD and ESMOCARD LYO, a short acting beta blocker for the treatment of supraventricular tachycardia and control of the ventricular rate in patients with atrial fibrillation; Trevyent, a development stage drug/device combination product for pulmonary arterial hypertension; Xydalba, a treatment for acute bacterial skin and skin structure infections; and Zevtera/Mabelio, a cephalosporin antibiotic for intravenous administration with rapid bactericidal activity. Correvio Pharma Corp. was incorporated in 2018 and is headquartered in Vancouver, Canada.

Ad InvestorPlace

“Forget Tesla, this is Elon’s Next Big Thing”

According to Forbes, this breakthrough could define the future of AI. Most people don’t know about it… Because it was found 750 miles away from Silicon Valley.

Click here to see the details.

CORV Stock News Headlines

April 9, 2024 | msn.com

Natco Pharma gets USFDA warning letter for Kothur plant

March 29, 2024 | markets.businessinsider.com

Hold Rating Maintained for Corvus Pharmaceuticals Amid Clinical Delays and Financing Concerns

April 16, 2024 | InvestorPlace (Ad)

Nerd Investor Reveals Secret To Make Money With A.I.

He's doing something he's never done before. In ten years, this nerd investor has picked 210+ stocks that have gone up at least 100%.

March 19, 2024 | washingtonpost.com

Corvus: Q4 Earnings Snapshot

March 15, 2024 | bizjournals.com

'This is a sleeping giant:' UC seals licensing deal with TRPV Pharmaceuticals for new heart failure drug

March 13, 2024 | marketwatch.com

Corbus Pharmaceuticals Stock Climbs on Narrower-Than-Expected 4Q Loss

March 1, 2024 | msn.com

Garware Fulflex India acquires Avcor Health Care Products to strengthen its medical product portfolio

February 17, 2024 | wsj.com

Chong Kun Dang Pharmaceutical Corp.

April 16, 2024 | InvestorPlace (Ad)

Nerd Investor Reveals Secret To Make Money With A.I.

He's doing something he's never done before. In ten years, this nerd investor has picked 210+ stocks that have gone up at least 100%.

February 12, 2024 | finance.yahoo.com

Silver Creek Pharmaceuticals Appoints Mark Corrigan, M.D. As President

January 14, 2024 | morningstar.com

Chong Kun Dang Pharmaceutical Corp

December 12, 2023 | seekingalpha.com

Corvus Pharmaceuticals: Ahead Of The Clinical-Stage Curve

December 7, 2023 | bizjournals.com

AbbVie is acquiring two local biotechs — but won't detail its plans for them

December 7, 2023 | msn.com

AbbVie – Cerevel M&A deal lifts Reviva, Karuna

November 30, 2023 | benzinga.com

Scout Clinical secures preferred supplier status with Top 5 Pharma Leader

November 27, 2023 | msn.com

Corvus Pharmaceuticals (CRVS) Price Target Increased by 10.92% to 8.03

November 22, 2023 | msn.com

AbbVie suing Sandoz, four others to block generic Rinvoq: report

November 16, 2023 | investing.com

Vietnam Pharmaceutical Corp (DVN)

November 16, 2023 | morningstar.com

Nymox Pharmaceutical Corp NYMXF

November 14, 2023 | morningstar.com

Nutra Pharma Corp NPHC

November 12, 2023 | msn.com

WHO Approves First African-Manufactured Malaria Drug

November 6, 2023 | morningstar.com

HPGC Renmintongtai Pharmaceutical Corp Class A 600829

October 30, 2023 | markets.businessinsider.com

Analyst Assessment On Reviva Pharmaceuticals' Positive Schizophrenia Trial Data - Sees More Than 200% Upside In Stock

September 29, 2023 | markets.businessinsider.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Maravai Lifesciences Holdings (MRVI), Johnson & Johnson (JNJ) and Amicus (FOLD)

September 15, 2023 | finance.yahoo.com

RAMM Pharma Corp. Announces Corporate Update

August 31, 2023 | wsj.com

JW Pharmaceutical Corp.

August 25, 2023 | finanznachrichten.de

NervGen Pharma Corp.: NervGen Pharma to Present on its Drug Candidate NVG-291 and Spinal Cord Injury at Investor Conference

See More Headlines

Receive CORV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Correvio Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/30/2020
Today: 4/16/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical Preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:CORV
CUSIP: N/A
CIK: N/A
Web: www.correvio.com
Phone: 604-677-6905
Fax: N/A
Employees: 133
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($0.79)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-35,180,000.00
Net Margins: -107.81%
Pretax Margin: N/A
Return on Equity: -2,128.82%
Return on Assets: -58.56%

Debt

Debt-to-Equity Ratio: 22.54
Current Ratio: 1.07
Quick Ratio: 0.95

Sales & Book Value

Annual Sales: $32.63 million
Price / Sales: 0.85
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.02) per share
Price / Book: -21.00

Miscellaneous

Outstanding Shares: 66,191,000
Free Float: N/A
Market Cap: $27.80 million
Optionable: Optionable
Beta: 0.08

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Dr. Mark H. N. Corrigan (Age 62)
CEO & Director
Mr. Justin A. Renz CPA (Age 48)
MST, M.S.T., MBA, CFO & Pres
Ms. Sheila M. Grant
Chief Operating Officer
Mr. David D. McMasters (Age 61)
Chief Compliance Officer & Gen. Counsel
Mr. Hugues Sachot
Chief Commercial Officer

Key Competitors

View All Competitors

CORV Stock Analysis - Frequently Asked Questions

How were Correvio Pharma's earnings last quarter?: Correvio Pharma Corp (NASDAQ:CORV) released its earnings results on Monday, March, 30th. The company reported ($0.07) earnings per share for the quarter, beating analysts' consensus estimates of ($0.13) by $0.06. The company had revenue of $11.33 million for the quarter, compared to analysts' expectations of $11.52 million. Correvio Pharma had a negative net margin of 107.81% and a negative trailing twelve-month return on equity of 2,128.82%.
What other stocks do shareholders of Correvio Pharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Correvio Pharma investors own include Inovio Pharmaceuticals (INO), Outlook Therapeutics (OTLK), SCYNEXIS (SCYX), Heat Biologics (HTBX), Actinium Pharmaceuticals (ATNM), Acasti Pharma (ACST), Biocept (BIOC), Vaxart (VXRT), Co-Diagnostics (CODX).

This page (NASDAQ:CORV) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Correvio Pharma (CORV) Stock Price, News & Analysis

About Correvio Pharma

CORV Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

CORV Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info